For instance, ESRP1 has been suggested to drive both oncogenic (Fagoonee et al., 2017) and tumor-suppressive (Ueda et al., 2014; Shapiro et al., 2011) programs in the context of different cancers. Here, ESRP1 is linked to neoplasm.